The role of p53 mutations as a prognostic factor and therapeutic target in inflammatory breast cancer (Q36430748)

14 August 2017

1 reference

title

The role of p53 mutations as a prognostic factor and therapeutic target in inflammatory breast cancer (English)

1 reference

14 August 2017

Charles H Yang

1

1 reference

PubMed ID

16563093

14 August 2017

Massimo Cristofanilli

series ordinal

2

1 reference

PubMed ID

16563093

14 August 2017

language of work or name

English

0 references

publication date

1 April 2006

1 reference

14 August 2017

1 reference

14 August 2017

2

1 reference

14 August 2017

247-255

1 reference

14 August 2017

2

1 reference

Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy

14 August 2017

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

p53, the cellular gatekeeper for growth and division

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Locally advanced breast carcinoma: results with combined regional therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Mutations in the p53 gene occur in diverse human tumour types

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: a unique clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

p53 mutations and overexpression in locally advanced breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

P53 gene replacement for cancer--interactions with DNA damaging agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Adenovirus p53 gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anti-cancer drugs in human lung cancer cells irrespective of the status of p53 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Adenoviral strategies for the gene therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Characterization of the p53-rescue drug CP-31398 in vitro and in living cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Small molecules that reactivate mutant p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Cancer. p53, guardian of the genome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Repeated observation of breast tumor subtypes in independent gene expression data sets

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.2.247

21 January 2018

Identifiers

DOI

10.2217/14796694.2.2.247

1 reference

14 August 2017

1 reference

PubMed ID

16563093